Professor Cappelli, what were the reasons behind this conference?
The initiative was born from the need to address a fundamental issue: with the arrival of highly effective drugs for cardiac transthyretin amyloidosisWe are faced with therapies that work excellently both in reducing mortality and hospitalizations and in improving patients' quality of life. The problem is that, as with all rare diseases, these drugs are extremely expensive. Hence the need to discuss accessibility, cost-effectiveness, and uniformity of therapeutic indications.